Asthma, COPD Disease Severity May Increase Risk of Developing Severe COVID-19
Disease severity of both chronic obstructive pulmonary disease (COPD) and asthma may increase the risk of the development of severe coronavirus disease 2019 (COVID-19).
Disease severity of both chronic obstructive pulmonary disease (COPD) and asthma may increase the risk of the development of severe coronavirus disease 2019 (COVID-19).
Although COVID-19 acute respiratory distress syndrome (ARDS) has some key differences from non-COVID-19 ARDS, these differences do not merit deviation from evidence-based ARDS management.
The Oxford-AstraZeneca COVID-19 vaccine, ChAdOx1, released 4 studies to analyze its efficacy in the prevention of mild, moderate, and severe COVID-19 infection; new studies also address rising concerns in the vaccine’s ability to protect against variants B.1.1.7 and B.1.351.
Viral load of the COVID-19 in the upper respiratory tract may be an effective stratification method for severe outcomes, length of stay, and death.
The first U.S. participants in a large-scale clinical trial to test the safety and efficacy of the Pfizer COVID-19 vaccine in pregnant women have received their shots.
Seven percent of patients with severe COVID-19 present with abnormal magnetic resonance imaging findings of the globe of the eye.
More than half of cancer survivors have underlying medical conditions associated with severe COVID-19 illness.
Patients undergoing long-term dialysis who become infected with SARS-CoV-2 have a high COVID-19 case fatality rate.
Researchers describe the emergence of a novel variant of SARS-CoV-2, CAL.20C, which originated in Southern California.
Smokers are at an increased risk of developing symptomatic coronavirus 2019 (COVID-19).